RU2010122644A - Способы лечения склеродермии - Google Patents
Способы лечения склеродермии Download PDFInfo
- Publication number
- RU2010122644A RU2010122644A RU2010122644/13A RU2010122644A RU2010122644A RU 2010122644 A RU2010122644 A RU 2010122644A RU 2010122644/13 A RU2010122644/13 A RU 2010122644/13A RU 2010122644 A RU2010122644 A RU 2010122644A RU 2010122644 A RU2010122644 A RU 2010122644A
- Authority
- RU
- Russia
- Prior art keywords
- antibodies
- patient
- symptoms
- intensity
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 27
- 206010039710 Scleroderma Diseases 0.000 title claims abstract 5
- 208000024891 symptom Diseases 0.000 claims abstract 10
- 239000005557 antagonist Substances 0.000 claims abstract 6
- 102000002227 Interferon Type I Human genes 0.000 claims abstract 4
- 108010014726 Interferon Type I Proteins 0.000 claims abstract 4
- 230000008021 deposition Effects 0.000 claims abstract 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract 4
- 201000004384 Alopecia Diseases 0.000 claims abstract 2
- 102000008186 Collagen Human genes 0.000 claims abstract 2
- 108010035532 Collagen Proteins 0.000 claims abstract 2
- 206010016654 Fibrosis Diseases 0.000 claims abstract 2
- 101000998969 Homo sapiens Inositol-3-phosphate synthase 1 Proteins 0.000 claims abstract 2
- 206010061218 Inflammation Diseases 0.000 claims abstract 2
- 102100036881 Inositol-3-phosphate synthase 1 Human genes 0.000 claims abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract 2
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract 2
- 238000011529 RT qPCR Methods 0.000 claims abstract 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims abstract 2
- 206010040867 Skin hypertrophy Diseases 0.000 claims abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract 2
- 231100000360 alopecia Toxicity 0.000 claims abstract 2
- 238000004458 analytical method Methods 0.000 claims abstract 2
- 229920001436 collagen Polymers 0.000 claims abstract 2
- 230000000295 complement effect Effects 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 230000002500 effect on skin Effects 0.000 claims abstract 2
- 230000004761 fibrosis Effects 0.000 claims abstract 2
- 230000002757 inflammatory effect Effects 0.000 claims abstract 2
- 230000004054 inflammatory process Effects 0.000 claims abstract 2
- 201000001474 proteinuria Diseases 0.000 claims abstract 2
- 206010040882 skin lesion Diseases 0.000 claims abstract 2
- 231100000444 skin lesion Toxicity 0.000 claims abstract 2
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 claims 1
- 102100030323 Epigen Human genes 0.000 claims 1
- 101000938352 Homo sapiens Epigen Proteins 0.000 claims 1
- 101001006892 Homo sapiens Krueppel-like factor 10 Proteins 0.000 claims 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 claims 1
- 102100027798 Krueppel-like factor 10 Human genes 0.000 claims 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
1. Способ лечения склеродермии у пациента, который нуждается в таком лечении, заключающийся в том, что пациенту вводят терапевтически эффективное количество антагониста интерферона типа I (ИФН). ! 2. Способ уменьшения интенсивности одного или более симптомов, ассоциированных со склеродермией, у пациента, который нуждается в таком лечении, заключающийся в том, что пациенту вводят терапевтически эффективное количество антагониста интерферона типа I. ! 3. Способ по п.1 или 2, где указанным антагонистом являются антитела. ! 4. Способ по п.3, где указанные антитела являются антителами анти-ИФНαР. ! 5. Способ по п.3, где указанные антитела являются антителами анти-ИФНα. ! 6. Способ по п.1 или 2, где симптомы заболевания выбраны из группы, включающей дермальный фиброз, поражения кожи, алопецию, воспаление, кожные утолщения, отложение коллагена, протеинурию и отложение комплемента. ! 7. Способ по п.1 или 2, где антитела вводят в дозе от приблизительно 0,03 мг/кг до приблизительно 30 мг/кг. ! 8. Способ по п.1 или 2, где указанное лечение приводит к уменьшению интенсивности симптомов по результатам оценки модифицированной кожи по шкале Роднана. ! 9. Способ по п.1 или 2, где указанное лечение приводит к уменьшению интенсивности симптомов по результатам оценки состояния Рейно (ОСР). ! 10. Способ по п.1 или 2, где указанное лечение приводит к уменьшению интенсивности симптомов по результатам анализа образцов кожи пациента методом кПЦР. !11. Способ по п.10, где указанное лечение снижает экспрессию воспалительных генов, выбранных из группы, включающей МРО, ФНОα, ИЛ-6 и INOS. ! 12. Способ по п.10, где указанное лечение снижает экспрессию генов, ассоциированных с рек�
Claims (12)
1. Способ лечения склеродермии у пациента, который нуждается в таком лечении, заключающийся в том, что пациенту вводят терапевтически эффективное количество антагониста интерферона типа I (ИФН).
2. Способ уменьшения интенсивности одного или более симптомов, ассоциированных со склеродермией, у пациента, который нуждается в таком лечении, заключающийся в том, что пациенту вводят терапевтически эффективное количество антагониста интерферона типа I.
3. Способ по п.1 или 2, где указанным антагонистом являются антитела.
4. Способ по п.3, где указанные антитела являются антителами анти-ИФНαР.
5. Способ по п.3, где указанные антитела являются антителами анти-ИФНα.
6. Способ по п.1 или 2, где симптомы заболевания выбраны из группы, включающей дермальный фиброз, поражения кожи, алопецию, воспаление, кожные утолщения, отложение коллагена, протеинурию и отложение комплемента.
7. Способ по п.1 или 2, где антитела вводят в дозе от приблизительно 0,03 мг/кг до приблизительно 30 мг/кг.
8. Способ по п.1 или 2, где указанное лечение приводит к уменьшению интенсивности симптомов по результатам оценки модифицированной кожи по шкале Роднана.
9. Способ по п.1 или 2, где указанное лечение приводит к уменьшению интенсивности симптомов по результатам оценки состояния Рейно (ОСР).
10. Способ по п.1 или 2, где указанное лечение приводит к уменьшению интенсивности симптомов по результатам анализа образцов кожи пациента методом кПЦР.
11. Способ по п.10, где указанное лечение снижает экспрессию воспалительных генов, выбранных из группы, включающей МРО, ФНОα, ИЛ-6 и INOS.
12. Способ по п.10, где указанное лечение снижает экспрессию генов, ассоциированных с реконструкцией ткани, выбранных из группы, включающей KLF10, TIMP, EPGN и ММР9.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99617507P | 2007-11-05 | 2007-11-05 | |
| US60/996,175 | 2007-11-05 | ||
| US10045408P | 2008-09-26 | 2008-09-26 | |
| US61/100,454 | 2008-09-26 | ||
| PCT/US2008/082481 WO2009061818A1 (en) | 2007-11-05 | 2008-11-05 | Methods of treating scleroderma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010122644A true RU2010122644A (ru) | 2011-12-20 |
| RU2530561C2 RU2530561C2 (ru) | 2014-10-10 |
Family
ID=43087976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010122644/15A RU2530561C2 (ru) | 2007-11-05 | 2008-11-05 | Способы лечения склеродермии |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20110008365A1 (ru) |
| EP (1) | EP2219452B1 (ru) |
| JP (2) | JP5767475B2 (ru) |
| KR (1) | KR20100098620A (ru) |
| CN (1) | CN101909444B (ru) |
| AU (1) | AU2008324800B2 (ru) |
| BR (1) | BRPI0819195A2 (ru) |
| CA (1) | CA2703705A1 (ru) |
| CY (1) | CY1117251T1 (ru) |
| DK (1) | DK2219452T3 (ru) |
| ES (1) | ES2557352T3 (ru) |
| HR (1) | HRP20151403T1 (ru) |
| HU (1) | HUE025787T2 (ru) |
| IL (1) | IL205452A (ru) |
| MX (1) | MX2010004814A (ru) |
| NZ (1) | NZ585064A (ru) |
| PL (1) | PL2219452T3 (ru) |
| PT (1) | PT2219452E (ru) |
| RU (1) | RU2530561C2 (ru) |
| SI (1) | SI2219452T1 (ru) |
| WO (1) | WO2009061818A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009100309A2 (en) | 2008-02-08 | 2009-08-13 | Medimmune, Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
| BR112013030242A2 (pt) * | 2011-05-25 | 2016-12-06 | Medimmune Llc | método de tratamento de um distúrbio autoimune em um sujeito humano |
| CN108310375A (zh) * | 2012-06-13 | 2018-07-24 | 米迪缪尼有限公司 | 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案 |
| CA3043823A1 (en) * | 2015-11-17 | 2017-05-26 | The Regents Of The University Of Colorado, A Body Corporate | Novel multiplex assays to diagnose or evaluate diseases or disorders in mammals |
| AU2022260531B2 (en) | 2021-04-23 | 2024-03-07 | Astrazeneca Ab | Anti-ifnar1 dosing regime for subcutaneous injection |
| CN118320101B (zh) * | 2024-06-14 | 2024-09-17 | 天津嘉氏堂科技有限公司 | iNOS抑制剂在制备治疗硬皮病胶原沉积药物中的应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3461808A (en) | 1967-07-03 | 1969-08-19 | Wood John Co | Diaphragm hand pumps |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| JPS60500864A (ja) | 1983-02-04 | 1985-06-06 | ワドリ、テクナラジズ、インコーパレイティド | 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ |
| GB8303165D0 (en) | 1983-02-04 | 1983-03-09 | Secher D S | Monoclonal antibody |
| DE3306060A1 (de) | 1983-02-22 | 1984-08-23 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| DE3685996T2 (de) | 1985-06-11 | 1993-01-14 | Ciba Geigy Ag | Hybrid-interferone. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3923126A1 (de) | 1989-07-13 | 1991-01-17 | Stark Henric | Lautsprecherbox |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
| US4997008A (en) | 1990-04-26 | 1991-03-05 | Moen Incorporated | Faucet spout assembly |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| ATE269401T1 (de) | 1991-04-10 | 2004-07-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| EP0590067A1 (en) | 1991-06-14 | 1994-04-06 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| CA2507749C (en) | 1991-12-13 | 2010-08-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| AU696293B2 (en) | 1993-12-08 | 1998-09-03 | Genzyme Corporation | Process for generating specific antibodies |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US7285526B2 (en) * | 1995-07-14 | 2007-10-23 | Meiogen Biotechnology Corporation | Interferon antagonists useful for the treatment of interferon related diseases |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US6713609B1 (en) | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| PT970126E (pt) | 1997-04-14 | 2001-10-30 | Micromet Ag | Novo metodo para a producao de receptores de antigenios anti-humanos e suas utilizacoes |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6311415B1 (en) | 1998-09-14 | 2001-11-06 | Lind Shoe Company | Bowling shoe with replaceable tip |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| AU2002320352A1 (en) * | 2001-07-24 | 2003-02-17 | Biogen Idec Ma Inc. | Methods for treating or preventing sclerotic disorders using cd2-binding agents |
| AU2002324727A1 (en) * | 2001-08-17 | 2003-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian relaxin receptors |
| ES2624547T3 (es) * | 2001-11-14 | 2017-07-14 | Janssen Biotech, Inc. | Anticuerpos anti il 6, composiciones, métodos y usos |
| SI2418220T1 (sl) | 2003-12-10 | 2017-10-30 | E. R. Squibb & Sons, L.L.C. | Interferon alfa protitelesa in njihova uporaba |
| WO2005067963A1 (en) * | 2003-12-23 | 2005-07-28 | Intermune, Inc. | Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
| DK1781705T3 (en) * | 2004-06-21 | 2015-01-12 | Squibb & Sons Llc | Interferon-alpha receptor 1 antibodies and uses thereof |
| KR20080031022A (ko) * | 2005-06-22 | 2008-04-07 | 제넨테크, 인크. | Ｉｆｎａｒ２의 표적화를 위한 방법 및 조성물 |
| ES2383966T3 (es) * | 2005-08-05 | 2012-06-27 | Genentech, Inc. | Métodos y composiciones para detectar trastornos autoinmunes |
| BRPI0719912A2 (pt) | 2006-12-06 | 2014-03-04 | Medimmune Llc | Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico |
-
2008
- 2008-11-05 DK DK08847680.9T patent/DK2219452T3/en active
- 2008-11-05 US US12/741,262 patent/US20110008365A1/en not_active Abandoned
- 2008-11-05 PT PT88476809T patent/PT2219452E/pt unknown
- 2008-11-05 CA CA2703705A patent/CA2703705A1/en not_active Abandoned
- 2008-11-05 SI SI200831557T patent/SI2219452T1/sl unknown
- 2008-11-05 CN CN2008801242621A patent/CN101909444B/zh active Active
- 2008-11-05 ES ES08847680.9T patent/ES2557352T3/es active Active
- 2008-11-05 MX MX2010004814A patent/MX2010004814A/es active IP Right Grant
- 2008-11-05 KR KR1020107012340A patent/KR20100098620A/ko not_active Ceased
- 2008-11-05 WO PCT/US2008/082481 patent/WO2009061818A1/en not_active Ceased
- 2008-11-05 PL PL08847680T patent/PL2219452T3/pl unknown
- 2008-11-05 HR HRP20151403TT patent/HRP20151403T1/hr unknown
- 2008-11-05 RU RU2010122644/15A patent/RU2530561C2/ru active
- 2008-11-05 EP EP08847680.9A patent/EP2219452B1/en active Active
- 2008-11-05 HU HUE08847680A patent/HUE025787T2/en unknown
- 2008-11-05 AU AU2008324800A patent/AU2008324800B2/en active Active
- 2008-11-05 BR BRPI0819195A patent/BRPI0819195A2/pt not_active Application Discontinuation
- 2008-11-05 JP JP2010532334A patent/JP5767475B2/ja active Active
- 2008-11-05 NZ NZ585064A patent/NZ585064A/xx unknown
-
2010
- 2010-04-29 IL IL205452A patent/IL205452A/en active IP Right Grant
-
2014
- 2014-04-01 JP JP2014075310A patent/JP2014144966A/ja active Pending
-
2016
- 2016-01-11 CY CY20161100012T patent/CY1117251T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2219452A4 (en) | 2012-05-02 |
| EP2219452B1 (en) | 2015-10-14 |
| JP5767475B2 (ja) | 2015-08-19 |
| CN101909444B (zh) | 2013-09-18 |
| CY1117251T1 (el) | 2017-04-26 |
| EP2219452A1 (en) | 2010-08-25 |
| US20110008365A1 (en) | 2011-01-13 |
| WO2009061818A1 (en) | 2009-05-14 |
| HUE025787T2 (en) | 2016-05-30 |
| CA2703705A1 (en) | 2009-05-14 |
| AU2008324800B2 (en) | 2014-03-27 |
| IL205452A (en) | 2016-02-29 |
| MX2010004814A (es) | 2010-08-10 |
| NZ585064A (en) | 2012-08-31 |
| PL2219452T3 (pl) | 2016-04-29 |
| SI2219452T1 (sl) | 2016-03-31 |
| DK2219452T3 (en) | 2016-01-11 |
| CN101909444A (zh) | 2010-12-08 |
| JP2011503008A (ja) | 2011-01-27 |
| PT2219452E (pt) | 2016-01-26 |
| BRPI0819195A2 (pt) | 2017-05-23 |
| ES2557352T3 (es) | 2016-01-25 |
| JP2014144966A (ja) | 2014-08-14 |
| KR20100098620A (ko) | 2010-09-08 |
| RU2530561C2 (ru) | 2014-10-10 |
| AU2008324800A1 (en) | 2009-05-14 |
| HK1151190A1 (zh) | 2012-04-05 |
| HRP20151403T1 (hr) | 2016-02-12 |
| IL205452A0 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vinaik et al. | NLRP3 inflammasome activity is required for wound healing after burns | |
| Haque et al. | Interferon gamma (IFN‐γ) may reverse oral submucous fibrosis | |
| Branski et al. | Acute vocal fold wound healing in a rabbit model | |
| RU2010122644A (ru) | Способы лечения склеродермии | |
| Lee et al. | Acupuncture accelerates wound healing in burn-injured mice | |
| IL172705A0 (en) | Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases | |
| Baamonde et al. | Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1β levels in inflamed and osteosarcoma-bearing mice | |
| Hsieh et al. | Recruitment and therapeutic application of macrophages in skeletal muscles after hind limb ischemia | |
| Gangemi et al. | Interleukin 31 and skin diseases: A systematic review. | |
| Xu et al. | Resolvin E1 ameliorates pulpitis by suppressing dental pulp fibroblast activation in a chemerin receptor 23-dependent manner | |
| KR102520355B1 (ko) | 폐 섬유화 질환 치료를 위한, g-csf의 이용 | |
| da Cunha Sousa et al. | Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice | |
| Jia et al. | Anti-inflammation and anti-aging mechanisms of mercaptopurine in vivo and in vitro | |
| Zhao et al. | Hydrogen inhalation inhibits microglia activation and neuroinflammation in a rat model of traumatic brain injury | |
| Zhang et al. | IL‐17A‐neutralizing antibody ameliorates inflammation and fibrosis in rosacea by antagonizing the CXCL5/CXCR2 axis | |
| Tognetti et al. | UVA‐1 phototherapy as adjuvant treatment for eosinophilic fasciitis: in vitro and in vivo functional characterization | |
| Ishikawa et al. | Antifibrogenic effects of C‐C chemokine receptor type 2 antagonist in a bleomycin‐induced scleroderma model | |
| Chen et al. | Activation of mitochondrial DNA-mediated cGAS-STING pathway contributes to chronic postsurgical pain by inducing type I interferons and A1 reactive astrocytes in the spinal cord | |
| JP2011503008A5 (ru) | ||
| Addrizzo-Harris et al. | Mechanisms of colchicine effect in the treatment of asbestosis and idiopathic pulmonary fibrosis | |
| Mizutani et al. | Nodular scleroderma: focally increased tenascin expression differing from that in the surrounding scleroderma skin | |
| Xu et al. | GABA transporter-1 inhibitor NO-711 alters the EEG power spectra and enhances non-rapid eye movement sleep during the active phase in mice | |
| Um et al. | IL-21 drives skin and lung inflammation and fibrosis in a model for systemic sclerosis | |
| Koh et al. | Decreased expressions of thrombospondin 2 in cyclosporin A‐induced gingival overgrowth | |
| Ohtake et al. | Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20190531 |